PrunetrinCAS# 154-36-9 |
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 154-36-9 | SDF | Download SDF |
PubChem ID | 16398538.0 | Appearance | Powder |
Formula | C22H22O10 | M.Wt | 446.4 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc. | ||
Chemical Name | 5-hydroxy-7-methoxy-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]chromen-4-one | ||
SMILES | COC1=CC(=C2C(=C1)OC=C(C2=O)C3=CC=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O)O | ||
Standard InChIKey | OFUWGCQDMVDLIR-RECXWPGBSA-N | ||
Standard InChI | InChI=1S/C22H22O10/c1-29-12-6-14(24)17-15(7-12)30-9-13(18(17)25)10-2-4-11(5-3-10)31-22-21(28)20(27)19(26)16(8-23)32-22/h2-7,9,16,19-24,26-28H,8H2,1H3/t16-,19-,20+,21-,22-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Prunetrin Dilution Calculator
Prunetrin Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.2401 mL | 11.2007 mL | 22.4014 mL | 44.8029 mL | 56.0036 mL |
5 mM | 0.448 mL | 2.2401 mL | 4.4803 mL | 8.9606 mL | 11.2007 mL |
10 mM | 0.224 mL | 1.1201 mL | 2.2401 mL | 4.4803 mL | 5.6004 mL |
50 mM | 0.0448 mL | 0.224 mL | 0.448 mL | 0.8961 mL | 1.1201 mL |
100 mM | 0.0224 mL | 0.112 mL | 0.224 mL | 0.448 mL | 0.56 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- Salsolinol
Catalog No.:BCX0715
CAS No.:27740-96-1
- Bufotenidine
Catalog No.:BCX0714
CAS No.:487-91-2
- Epigallocatechin gallate octaacetate
Catalog No.:BCX0713
CAS No.:148707-39-5
- Oleandrin,anhydro-16-deacetyl-
Catalog No.:BCX0712
CAS No.:69549-58-2
- Pinolenic acid
Catalog No.:BCX0711
CAS No.:16833-54-8
- Digitoxigenin
Catalog No.:BCX0710
CAS No.:143-62-4
- Oleandrigenin
Catalog No.:BCX0709
CAS No.:465-15-6
- Oroxylin A-7-glucoside
Catalog No.:BCX0708
CAS No.:36948-77-3
- 5-Hydroxy-2′,3,4′,7-tetramethoxyflavone
Catalog No.:BCX0707
CAS No.:19056-75-8
- Methyl jasmonate
Catalog No.:BCX0706
CAS No.:1211-29-6
- Ginsenoside Ra6
Catalog No.:BCX0705
CAS No.:1346522-89-1
- Endothalic acid
Catalog No.:BCX0704
CAS No.:145-73-3
- limocitrin -3-O-rutinoside
Catalog No.:BCX0717
CAS No.:79384-27-3
- Anthrone
Catalog No.:BCX0718
CAS No.:90-44-8
- D-Lyxose
Catalog No.:BCX0719
CAS No.:1114-34-7
- Ligupurpuroside D
Catalog No.:BCX0720
CAS No.:1194056-35-3
- 7-Ketodeoxycholic acid
Catalog No.:BCX0721
CAS No.:911-40-0
- Rabdosiin
Catalog No.:BCX0722
CAS No.:119152-54-4
- Melibiose
Catalog No.:BCX0723
CAS No.:585-99-9
- Neoanhydropodophyllol
Catalog No.:BCX0724
CAS No.:62287-47-2
- (+)-Rabdosiin
Catalog No.:BCX0725
CAS No.:263397-69-9
- 6-Methoxy-2-(2-phenylethyl)chromone
Catalog No.:BCX0726
CAS No.:84294-89-3
- 6-Methoxy-2-[2-(3'-methoxyphenyl)ethyl]chromone
Catalog No.:BCX0727
CAS No.:84294-88-2
- Melezitose
Catalog No.:BCX0728
CAS No.:597-12-6
Investigation of prunetrin induced G2/M cell cycle arrest and apoptosis via Akt/mTOR/MAPK pathways in hepatocellular carcinoma cells.[Pubmed:38552440]
Biomed Pharmacother. 2024 May;174:116483.
Hepatocellular carcinoma (HCC) stands as a leading cause of mortality, and despite recent advancements in the overall survival rates, the prognosis remains dismal. Prunetin 4-O-glucoside (Prunetrin or PUR), an active compound derived from Prunus sp., was explored for its impact on HepG2 and Huh7 cells. The cytotoxicity assessment revealed a notable reduction in cell viability in both cell lines, while exhibiting non-toxicity towards HaCaT cells. Colony formation studies underscored PUR's inhibitory effect on cell proliferation, dose-dependently. Mechanistically, PUR downregulated cell cycle proteins (CDC25c, Cdk1/CDC2, and Cyclin B1), inducing G2/M phase arrest, corroborated by flow cytometry. Western blot analyses exhibited dose-dependent cleavages of PARP and caspase 3, indicative of apoptosis. Treatment with the apoptotic inhibitor z-vmd-fmk provided evidence of PUR-induced apoptosis. Annexin V and PI flow cytometry further affirmed apoptotic induction. Enhanced expression of cleaved-caspase 9 and the pro-apoptotic protein Bak, coupled with reduced anti-apoptotic Bcl-xL, and affirmed PUR's induction of intrinsic apoptosis. Additionally, PUR activated the MAPK pathway, evidenced by elevated phospho p38 and phospho ERK expressions in both cell lines. Notably, a concentration-dependent decrease in mTOR and Akt expressions indicated PUR's inhibition of the Akt/mTOR pathway in HepG2 and Huh7 cells. These findings illuminate PUR's multifaceted impact, revealing its potential as a promising therapeutic agent against HepG2 and Huh7 cells through modulation of cell cycle, apoptosis, and key signaling pathways.
Mechanistic Action of Cell Cycle Arrest and Intrinsic Apoptosis via Inhibiting Akt/mTOR and Activation of p38-MAPK Signaling Pathways in Hep3B Liver Cancer Cells by Prunetrin-A Flavonoid with Therapeutic Potential.[Pubmed:37571343]
Nutrients. 2023 Jul 31;15(15):3407.
Hepatocellular carcinoma (HCC) has a poor prognosis and a low survival rate. Drugs without side effects are desperately needed since chemotherapy has a negative effect on the host cells. Previous research has firmly established that plant-based compounds have significant bioactivities without a negative impact on the host. Flavonoids, in particular, are a class of compounds with both anti-inflammatory and anti-cancer properties. Prunetrin (PUR) is a glycosyloxyisoflavone (Prunetin 4'-O-glucoside) derived from Prunus sp., and its other form, called prunetin, showed optimistic results in an anti-cancerous study. Hence, we aimed to discover the anti-cancer ability of Prunetrin in liver cancer Hep3B cells. Our cytotoxicity results showed that PUR can decrease cell viability. The colony formation assay confirms this strongly and correlates with cell cytotoxicity results. Prunetrin, in a dose-dependent manner, arrested the cell cycle in the G2/M phase and decreased the expression of cyclin proteins such as Cyclin B1, CDK1/CDC2, and CDC25c. Prunetrin treatment also promoted the strong cleavage of two important apoptotic hallmark proteins called PARP and caspase-3. It also confirms that apoptosis occurs through the mitochondrial pathway through increased expression of cleaved caspase-9 and increased levels of the pro-apoptotic protein Bak. Bak was significantly increased with the declining expression of the anti-apoptotic protein Bcl-xL. Next, it inhibits the mTOR/AKT signaling pathways, proving that Prunetrin includes apoptosis and decreases cell viability by suppressing these pathways. Further, it was also observed that the activation of p38-MAPK was dose-dependent. Taken together, they provide evidence that Prunetrin has an anti-cancerous ability in Hep3B liver cancer cells by arresting the cell cycle via p38 and inhibiting mTOR/AKT.